ES2134954T3 - Procedimiento de supresion prolongada de la inmunidad humoral. - Google Patents
Procedimiento de supresion prolongada de la inmunidad humoral.Info
- Publication number
- ES2134954T3 ES2134954T3 ES94926660T ES94926660T ES2134954T3 ES 2134954 T3 ES2134954 T3 ES 2134954T3 ES 94926660 T ES94926660 T ES 94926660T ES 94926660 T ES94926660 T ES 94926660T ES 2134954 T3 ES2134954 T3 ES 2134954T3
- Authority
- ES
- Spain
- Prior art keywords
- procedure
- antagonist
- humoral immunity
- prolonged suppression
- suppression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 230000001629 suppression Effects 0.000 title abstract 2
- 230000004727 humoral immunity Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 230000028996 humoral immune response Effects 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000001541 thymus gland Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
SE DESCRIBEN METODOS DE SUPRESION DE UNA RESPUESTA INMUNE HUMORAL EN UN ANTIGENO DEPENDIENTE DEL TIMO (TD). LOS METODOS INCLUYEN LA ADMINISTRACION A UN SUJETO DE UN ANTIGENO TD CON UN ANTAGONISTA DE UNA MOLECULA QUE TRASMITE LAS FUNCIONES EFECTORAS ASISTENTES CONTACTO DEPENDIENTES. EN UNA REALIZACION PREFERIDA, EL ANTAGONISTA ES UN ANTAGONISTA DE GP39. PUEDEN SUPRIMIRSE RESPUESTAS INMUNES HUMORALES PRIMARIAS Y SECUNDARIAS Y PROLONGARSE LA SUPRESION.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11599093A | 1993-09-02 | 1993-09-02 | |
US08/232,929 US5869049A (en) | 1993-09-02 | 1994-04-25 | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2134954T3 true ES2134954T3 (es) | 1999-10-16 |
Family
ID=26813793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94926660T Expired - Lifetime ES2134954T3 (es) | 1993-09-02 | 1994-09-02 | Procedimiento de supresion prolongada de la inmunidad humoral. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0742721B1 (es) |
JP (1) | JP2840131B2 (es) |
CN (1) | CN1137726C (es) |
AT (1) | ATE179616T1 (es) |
AU (3) | AU7643094A (es) |
DE (1) | DE69418349T2 (es) |
DK (1) | DK0742721T3 (es) |
ES (1) | ES2134954T3 (es) |
FI (1) | FI106927B (es) |
GR (1) | GR3030762T3 (es) |
IL (1) | IL110852A (es) |
NO (1) | NO321037B1 (es) |
NZ (1) | NZ273208A (es) |
WO (1) | WO1995006480A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
BR9807471A (pt) * | 1997-01-10 | 2000-03-21 | Biogen Inc | Uso do composto anti-cd40l |
WO2000072882A1 (fr) * | 1999-06-01 | 2000-12-07 | Eisai Co., Ltd. | Agents prophylactiques du purpura thrombocytopenique idiopathique |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
AU2001261585B2 (en) | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
EP3992210A1 (en) * | 2014-01-13 | 2022-05-04 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
JP7049988B2 (ja) | 2015-08-05 | 2022-04-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd154抗体及びこれを使用する方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661360B2 (en) * | 1991-10-25 | 1995-07-20 | Immunex Corporation | Novel cytokine |
CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
AU655349B2 (en) * | 1992-02-17 | 1994-12-15 | Kenji Nakamura | An antibacterial porous inorganic capsule and a process for producing the same |
-
1994
- 1994-09-02 WO PCT/US1994/009872 patent/WO1995006480A1/en active IP Right Grant
- 1994-09-02 AT AT94926660T patent/ATE179616T1/de not_active IP Right Cessation
- 1994-09-02 DE DE69418349T patent/DE69418349T2/de not_active Expired - Fee Related
- 1994-09-02 DK DK94926660T patent/DK0742721T3/da active
- 1994-09-02 IL IL11085294A patent/IL110852A/xx not_active IP Right Cessation
- 1994-09-02 AU AU76430/94A patent/AU7643094A/en not_active Abandoned
- 1994-09-02 EP EP94926660A patent/EP0742721B1/en not_active Revoked
- 1994-09-02 CN CNB941940055A patent/CN1137726C/zh not_active Expired - Fee Related
- 1994-09-02 NZ NZ273208A patent/NZ273208A/xx not_active IP Right Cessation
- 1994-09-02 JP JP7508266A patent/JP2840131B2/ja not_active Expired - Fee Related
- 1994-09-02 ES ES94926660T patent/ES2134954T3/es not_active Expired - Lifetime
-
1996
- 1996-03-01 NO NO19960863A patent/NO321037B1/no not_active IP Right Cessation
- 1996-03-01 FI FI960979A patent/FI106927B/fi active
-
1999
- 1999-01-29 AU AU14220/99A patent/AU734853B2/en not_active Ceased
- 1999-07-14 GR GR990401847T patent/GR3030762T3/el unknown
-
2004
- 2004-12-16 AU AU2004240180A patent/AU2004240180B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO1995006480A1 (en) | 1995-03-09 |
FI960979A0 (fi) | 1996-03-01 |
AU734853B2 (en) | 2001-06-21 |
AU7643094A (en) | 1995-03-22 |
EP0742721A1 (en) | 1996-11-20 |
IL110852A0 (en) | 1994-11-28 |
AU1422099A (en) | 1999-04-01 |
DE69418349D1 (de) | 1999-06-10 |
DE69418349T2 (de) | 1999-09-09 |
JP2840131B2 (ja) | 1998-12-24 |
FI960979A (fi) | 1996-04-30 |
NO960863D0 (no) | 1996-03-01 |
CN1137758A (zh) | 1996-12-11 |
NO321037B1 (no) | 2006-03-06 |
EP0742721B1 (en) | 1999-05-06 |
AU2004240180B2 (en) | 2007-08-09 |
NO960863L (no) | 1996-04-30 |
GR3030762T3 (en) | 1999-11-30 |
IL110852A (en) | 1999-05-09 |
FI106927B (fi) | 2001-05-15 |
ATE179616T1 (de) | 1999-05-15 |
CN1137726C (zh) | 2004-02-11 |
NZ273208A (en) | 2000-12-22 |
JPH09502184A (ja) | 1997-03-04 |
AU2004240180A1 (en) | 2005-01-27 |
DK0742721T3 (da) | 1999-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2134954T3 (es) | Procedimiento de supresion prolongada de la inmunidad humoral. | |
GR3030568T3 (en) | Inducing cytotoxic t lymphocyte responses. | |
TR200003843T2 (tr) | HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım | |
AU7980794A (en) | Methods and compositions for microencapsulation of antigens for use as vaccines | |
DE122010000016I1 (de) | Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten | |
ATE326231T1 (de) | Mutierendes enterotoxin als nichttoxisches orales adjuvans | |
IL102639A0 (en) | Compositions for inducing cytotoxic t lymphocyte responses | |
PT101052A (pt) | Proteinas hibridas uteis na preparacao de vacinas | |
ES2113882T3 (es) | Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos. | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
AU1130392A (en) | Synthetic htlv-iii peptides, compositions and uses thereof | |
DK0726758T3 (da) | Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus | |
AU4055989A (en) | Novel infectious bursal disease virus | |
ES2177927T3 (es) | Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico. | |
CA2089753A1 (en) | Interleukin-2-leukotoxin gene fusions and uses therefor | |
DE69837896D1 (de) | Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität | |
DK0882132T3 (da) | Et kombineret humant cytomegalovirus-antigen og anvendelse heraf | |
WO1999011660A3 (en) | Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions | |
GB2227936A (en) | Vaccine against brucella abortus | |
ES2005753A6 (es) | Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas. | |
EP0293333A3 (en) | A synthetic nonapeptide of use as an adjuvant | |
DE69637435D1 (de) | Saponin-zusammensetzungen und deren verwendung | |
DK0929315T3 (da) | Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse | |
WO2001035993A3 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
CA2246802A1 (en) | A human cytomegalovirus combined antigen and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 742721 Country of ref document: ES |